Advanced

Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group

Thulin, T; Lehtonen, A; Dahlof, C; Nilsson-Ehle, Peter LU ; Engqvist, L; Lagerstedt, C and Berglund, E (1999) In International Journal of Clinical Pharmacology and Therapeutics 37(1). p.28-33
Abstract
The purpose of this long-term treatment study was to evaluate health-related quality of life by comparing the effects of diltiazem and atenolol on some important metabolic parameters. SUBJECTS, MATERIAL AND METHODS: In a Swedish-Finnish long-term multicenter study 256 patients with mild to moderate hypertension were randomized to treatment with diltiazem retard (D) (n = 127) or atenolol (A) (n = 129). Doses could be increased and additional captopril medication be given to achieve adequate blood pressure (BP) reduction. The treatment in group D lasted for two years while group A was treated for 1 year and then was given D for another 2 years. RESULTS: After 1 year BP was significantly reduced in both groups and to a similar degree. The BP... (More)
The purpose of this long-term treatment study was to evaluate health-related quality of life by comparing the effects of diltiazem and atenolol on some important metabolic parameters. SUBJECTS, MATERIAL AND METHODS: In a Swedish-Finnish long-term multicenter study 256 patients with mild to moderate hypertension were randomized to treatment with diltiazem retard (D) (n = 127) or atenolol (A) (n = 129). Doses could be increased and additional captopril medication be given to achieve adequate blood pressure (BP) reduction. The treatment in group D lasted for two years while group A was treated for 1 year and then was given D for another 2 years. RESULTS: After 1 year BP was significantly reduced in both groups and to a similar degree. The BP reduction was maintained during the rest of the study. After 1 and 2 years, HDL had increased significantly (p < 0.001) in group D. There was a corresponding significant reduction of the LDL/HDL ratio. In group A there were no changes after 1 year regarding lipoprotein levels. After the switch to D, group A showed similar improvements regarding HDL and the LDL/HDL ratio as the original D group. CONCLUSION: It is concluded that D and A are equally effective in lowering BP. However, long-term treatment with D, but not with A, has a favorable effect on HDL concentrations and the LDL/HDL ratio. According to these findings D affects the risk factor profile in hypertension. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Diltiazem, Coronary vasodilator agent, Antiarrhythmic agent, Atenolol, Calcium antagonist, Antianginal agent, Biological activity, Cardioprotective agent, Hypertension, Metabolism, Glucose, Lipids, Uric acid, Human, Long term, Quality of life, Multicenter study, Randomization, Comparative study, Lipoprotein LDL, Lipoprotein HDL, Benzothiazepine derivatives, Risk factor, Cardiovascular disease
in
International Journal of Clinical Pharmacology and Therapeutics
volume
37
issue
1
pages
28 - 33
publisher
Dustri-Verlag
external identifiers
  • pmid:10027480
  • scopus:0032895215
ISSN
0946-1965
language
English
LU publication?
yes
id
c7b1be74-0e95-4a78-819a-3c982b009f8d (old id 1115809)
date added to LUP
2008-07-08 14:40:26
date last changed
2017-01-01 07:27:03
@article{c7b1be74-0e95-4a78-819a-3c982b009f8d,
  abstract     = {The purpose of this long-term treatment study was to evaluate health-related quality of life by comparing the effects of diltiazem and atenolol on some important metabolic parameters. SUBJECTS, MATERIAL AND METHODS: In a Swedish-Finnish long-term multicenter study 256 patients with mild to moderate hypertension were randomized to treatment with diltiazem retard (D) (n = 127) or atenolol (A) (n = 129). Doses could be increased and additional captopril medication be given to achieve adequate blood pressure (BP) reduction. The treatment in group D lasted for two years while group A was treated for 1 year and then was given D for another 2 years. RESULTS: After 1 year BP was significantly reduced in both groups and to a similar degree. The BP reduction was maintained during the rest of the study. After 1 and 2 years, HDL had increased significantly (p &lt; 0.001) in group D. There was a corresponding significant reduction of the LDL/HDL ratio. In group A there were no changes after 1 year regarding lipoprotein levels. After the switch to D, group A showed similar improvements regarding HDL and the LDL/HDL ratio as the original D group. CONCLUSION: It is concluded that D and A are equally effective in lowering BP. However, long-term treatment with D, but not with A, has a favorable effect on HDL concentrations and the LDL/HDL ratio. According to these findings D affects the risk factor profile in hypertension.},
  author       = {Thulin, T and Lehtonen, A and Dahlof, C and Nilsson-Ehle, Peter and Engqvist, L and Lagerstedt, C and Berglund, E},
  issn         = {0946-1965},
  keyword      = {Diltiazem,Coronary vasodilator agent,Antiarrhythmic agent,Atenolol,Calcium antagonist,Antianginal agent,Biological activity,Cardioprotective agent,Hypertension,Metabolism,Glucose,Lipids,Uric acid,Human,Long term,Quality of life,Multicenter study,Randomization,Comparative study,Lipoprotein LDL,Lipoprotein HDL,Benzothiazepine derivatives,Risk factor,Cardiovascular disease},
  language     = {eng},
  number       = {1},
  pages        = {28--33},
  publisher    = {Dustri-Verlag},
  series       = {International Journal of Clinical Pharmacology and Therapeutics},
  title        = {Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group},
  volume       = {37},
  year         = {1999},
}